Navigation Links
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
Date:8/21/2013

l remission (Mayo score of 2 or lower and no subscore higher than 1) at 52 weeks. In addition, a significantly greater proportion of patients receiving vedolizumab achieved mucosal healing (Mayo endoscopic subscore of 0 or 1) at six and 52 weeks, and glucocorticoid-free remission at 52 weeks, compared with placebo. Discussed in a separate publication, results from GEMINI II, a placebo-controlled induction and maintenance study in patients with CD, showed that vedolizumab demonstrated statistically significant improvement in the primary endpoint of clinical remission (Crohn's disease activity index [CDAI] score less than or equal to 150 points) at six weeks and at 52 weeks compared to placebo. At six weeks, no significant difference was observed in the co-primary endpoint of CDAI-100 response (greater than or equal to 100-point decrease in the CDAI score) between the vedolizumab and placebo groups. A significantly greater proportion of patients showed CDAI-100 response and glucocorticoid-free remission at 52 weeks.

GEMINI I and GEMINI II are part of the four-study GEMINI Studies™, studying vedolizumab in 2,700 patients in nearly 40 countries, making it the largest Phase 3 clinical trial program conducted to date simultaneously evaluating both CD and UC. Enrolled patients had failed at least one conventional therapy, including glucocorticoids, immunomodulators and/or a tumor necrosis factor-alpha (TNF-alpha) antagonist. TNF-alpha antagonist failure patients included those with inadequate response (primary non-responders), loss of response (secondary non-responders) or those who were intolerant.

"These clinical studies suggest that vedolizumab may have the potential to maintain clinical remission in the appropriate patients," said Asit Parikh, M.D., Ph.D., vice president, general medicine, Takeda. "Takeda has a strong legacy of researching and treating GI disorders globally, and vedolizumab represents our fo
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. 1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient Published in Journal of Cardiothoracic Surgery
2. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
3. Leadership Through Research Collaboration Is Reflected In Articles Published In Alzheimers Association Journal
4. Depression Study Published on BCM-95 Curcumin
5. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
6. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
7. BioElectronics New Patent Published
8. Benefits of Using Hologics Breast Tomosynthesis Mammography Technology Supported in Published Italian Study
9. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
10. Study Published in European Radiology Further Supports the Use of Hologics Breast Tomosynthesis in Cancer Screening in Practices Using Double Reads
11. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 The ambulance equipment ... decade due to the recession, an unstable ... advancements. This BCC Research report analyzes present ... the ambulance and emergency medical services equipment ... hemorrhage control devices, equipment used for burn ...
(Date:9/17/2014)... , Sept. 17, 2014  Dr. Stephen ... the White House today for National Recovery Month, stars ... consumer advocates released today. Consumer advocates were also joined ... who spoke out after losing her fiancée because of ... the doctor had a history of crack cocaine abuse. ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire-iReach/ -- ChemImage announced ... discussing improvements in the development of imaging ... both normal and diseased tissue that minimizes ... surgical procedures, lowers surgical costs and potentially ... The clinical and scientific ...
Breaking Medicine Technology:Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2
... 4 Novartis Vaccines & Diagnostics Inc. and Novartis ... to resolve civil False Claims Act allegations arising from the ... announced today. The settlement resolves allegations that, between Jan. ... and its predecessor, Chiron Corporation, caused false claims to be ...
... Joseph F. Finn, Jr. , C.P.A. ("Finn"),  Assignee for ... that the MRI imaging intellectual properties of the EP-3600 MRI imaging ... assets of Epix were transferred to him on July 20, ... Epix creditors.  He recently reached an agreement with Bayer Schering Pharma ...
Cached Medicine Technology:Novartis Vaccines & Diagnostics to Pay More Than $72 Million to Resolve False Claims Act Allegations Concerning TOBI 2Novartis Vaccines & Diagnostics to Pay More Than $72 Million to Resolve False Claims Act Allegations Concerning TOBI 3Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent 2
(Date:9/17/2014)... Dallas, TX (PRWEB) September 17, 2014 ... they were recently granted several awards for their top-notch ... regarding patient experience, orthopedic care and GYN surgery. , ... Patient Safety Excellence Award™. They have received this award ... ranked among the top 5 percent in the nation ...
(Date:9/17/2014)... News, VA (PRWEB) September 17, 2014 ... will host recruit757’s scholarship workshop for football players ... on Tuesday, Sept. 23. , Doors open at 6:30 ... Performance Center and speak to trainers and physical therapists. ... until 9 p.m. , The Newport News Tidewater Performance ...
(Date:9/17/2014)... messages about the health benefits of quitting smoking may ... suggests. Although smokers who think quitting will be ... effects of smoking, researchers found smokers who believe they ... or positive, messages about how quitting will improve their ... of both types of messages might get more people ...
(Date:9/17/2014)... September 17, 2014 Prevention is the ... is hospitalizing scores of infants, children and teenagers in ... Kirk Mahon, medical director of Legacy ER & Urgent ... been no reported cases of EV-D68 so far in ... that could change,” he said. “Implementing prevention strategies now ...
(Date:9/17/2014)... 17, 2014 Boston Children’s Museum ... a monthly concert series, introducing young Museum visitors ... Top, America’s premier national platform celebrating the stories, ... of the young musicians featured will also be ... Children’s Museum is fortunate to partner with the ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3
... News) -- Body-building and weight-loss products are the types of ... a small new study. Liver injury from medication is ... and herbal supplements -- which do not require a prescription ... are used by up to 40 percent of people in ...
... (ICUs) that have no or limited access to critical care ... the specialists, called intensivists, staff the unit at night, according ... Pittsburgh School of Medicine and UPMC. However, the researchers were ... ICUs that were robustly staffed with the specialists during the ...
... Va. (May 22, 2012) The Food and Drug Administration ... group of rare cell disorders. The test, or assay, was ... field of mast cells. Lawrence Schwartz, M.D., Ph.D., chair ... Charles and Evelyn Thomas Professor of Medicine at VCU, has ...
... , TUESDAY, May 22 (HealthDay News) -- Got hair? If ... cancer, a preliminary study suggests. Researchers are reporting ... more likely to have cancer than were those with more ... that they may benefit from being screened earlier and perhaps, ...
... are not effective in determining which asthma patients are ... (ICS) medications without risk of flare-ups or exacerbations, according ... United Kingdom. The study also showed that nearly three-quarters ... use of ICS medications once their symptoms are under ...
... The new blood thinner Xarelto appears to lower the chances ... U.S. Food and Drug Administration review has found. The ... advance of an FDA advisory panel meeting Wednesday, at which ... of Xarelto for treating people with acute coronary syndrome (a ...
Cached Medicine News:Health News:Body Building, Diet Supplements Linked to Liver Damage: Study 2Health News:Intensivists at night improve patient outcomes in some ICUs, says Pitt/UPMC team 2Health News:FDA clears test developed in partnership with VCU researcher 2Health News:Do Bald Men Face Higher Risk of Prostate Cancer? 2Health News:Do Bald Men Face Higher Risk of Prostate Cancer? 3Health News:Identifying asthma patients who tolerate lower doses of steroids remains problematic 2Health News:Identifying asthma patients who tolerate lower doses of steroids remains problematic 3Health News:New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: